Feeds
6810 items (6810 unread) in 74 feeds
Acinar Cell Carcinoma
(81 unread)
Acinic Cell Carcinoma
(46 unread)
Adenoid Cystic Carcinoma
(159 unread)
Adrenal Gland Cancer
(533 unread)
Ampulla Of Vater
(68 unread)
Anal Cancer
(425 unread)
Angiosarcoma
(153 unread)
Appendix Cancer
(104 unread)
Bile Duct Cancer
(845 unread)
Brain and CNS
(878 unread)
Carcinoid
(266 unread)
Endocrine/Neuroendocrine
(808 unread)
Gall Bladder Cancer
(381 unread)
Hemangioendothelioma
(215 unread)
Hepatoblastoma
(129 unread)
Pancreas
(117 unread)
Phyllodes
(105 unread)
PMP and Mucinous Tumors
(114 unread)
Rhabdomyosarcoma
(246 unread)
Sarcoma
(1137 unread)
Google - Cholangiocarcinoma (100 unread)
-
Tcr2 (TCRR) falls 1.98% to Close at $16.31 on September 15 - Equities.com
Posted: September 16th, 2021, 11:42pm GMT
-
FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations - KPVI News 6
Posted: September 15th, 2021, 8:31pm GMT
-
New cancer program launched by Cholangiocarcinoma Foundation to connect patients, caregivers with essential resources - Curetoday.com
Posted: September 15th, 2021, 10:58am GMT
-
BridgeBio Pharma (BBIO) Receives FDA Fast Track Designation for Investigational Therapy for Treatment of Limb-girdle Muscular Dystrophy Type 2i - StreetInsider.com
Posted: September 15th, 2021, 9:40am GMT
-
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) - Yahoo Finance
Posted: September 15th, 2021, 9:30am GMT
-
US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments - PRNewswire
Posted: September 15th, 2021, 5:27am GMT
-
Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Strong - openPR
Posted: September 15th, 2021, 2:54am GMT
-
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients - Johnson City Press (subscription)
Posted: September 14th, 2021, 10:15am GMT
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients Johnson City Press (subscription) -
Individualised dosimetry and safety of SIRT for intrahepatic cholangiocarcinoma - DocWire News
Posted: September 14th, 2021, 4:00am GMT
-
Individualised dosimetry and safety of SIRT for intrahepatic cholangiocarcinoma - DocWire News
Posted: September 14th, 2021, 4:00am GMT
-
Broken Arrow graduate and former OU tennis player dying of rare cancer - KOKI FOX 23
Posted: September 13th, 2021, 8:53pm GMT
-
Taiho Oncology To Share Data in Advanced Solid Tumors at ESMO Congress 2021 - Yahoo Finance
Posted: September 13th, 2021, 11:00am GMT
-
Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference - Yahoo Finance
Posted: September 13th, 2021, 10:00am GMT
-
TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors - Yahoo Finance
Posted: September 13th, 2021, 8:45am GMT
-
TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in ... - The Bakersfield Californian
Posted: September 13th, 2021, 8:45am GMT
TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in ... The Bakersfield Californian -
Building on Prior Research, Wilmot Makes Progress on Vexing Liver Cancer - URMC
Posted: September 13th, 2021, 8:15am GMT
-
Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference - Yahoo Finance
Posted: September 13th, 2021, 8:00am GMT
-
Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published - PRNewswire
Posted: September 13th, 2021, 5:23am GMT
-
Cholangiocarcinoma Pipeline Market 2021 Trending Technologies, Development Plans, Future Growth and Geographical Regions to 2027 - Northwest Diamond Notes
Posted: September 12th, 2021, 10:06am GMT
-
Sandra Wojowski Obituary (1946 - 2021) - Crest Hill, IL - The Herald-News - Legacy.com
Posted: September 12th, 2021, 10:36pm GMT
-
Sandra Wojowski Obituary (1946 - 2021) - Naperville, IL - Legacy.com
Posted: September 12th, 2021, 10:36pm GMT
-
Gregory Joseph John Tetrault Obituary - Minneapolis Star Tribune
Posted: September 11th, 2021, 4:26pm GMT
Gregory Joseph John Tetrault Obituary Minneapolis Star Tribune -
Learn all we can about 9/11′s health consequences - New York Daily News
Posted: September 11th, 2021, 7:00am GMT
Learn all we can about 9/11′s health consequences New York Daily News -
Amber Evans | Obituaries | republic-online.com - Miami County Republic
Posted: September 10th, 2021, 1:01pm GMT
Amber Evans | Obituaries | republic-online.com Miami County Republic -
Japanese Health Ministry Clears Thermo Fisher Scientific Oncomine Assay as CDx for Lung Cancer Drug - Precision Oncology News
Posted: September 10th, 2021, 12:45pm GMT
-
Japanese Health Ministry Clears Thermo Fisher Scientific Oncomine Assay as CDx for Lung Cancer Drug - GenomeWeb
Posted: September 10th, 2021, 12:45pm GMT
-
Former OU Tennis Captain Battling Cancer Set To Be Honored By School's Athletic Department - news9.com KWTV
Posted: September 9th, 2021, 8:52pm GMT
-
Former OU Tennis Captain Battling Cancer Set To Be Honored By School's Athletic Department - News On 6
Posted: September 9th, 2021, 4:24pm GMT
-
Early PVT Detection Crucial for Hospitalized Cirrhosis Patients With Liver Cancer - Clinical Oncology News
Posted: September 8th, 2021, 2:01am GMT
Early PVT Detection Crucial for Hospitalized Cirrhosis Patients With Liver Cancer Clinical Oncology News -
FDA grants priority review to Oxbryta for sickle cell disease - Healio
Posted: September 7th, 2021, 2:45pm GMT
-
RedHill Biopharma's Opaganib demonstrates significant decrease of kidney fibrosis - ZAWYA
Posted: September 7th, 2021, 9:18am GMT
-
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis - Johnson City Press (subscription)
Posted: September 7th, 2021, 9:00am GMT
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis Johnson City Press (subscription) -
Thermo Fisher (TMO)-AstraZeneca to Co-Develop NGS-Based CDx - Nasdaq
Posted: September 6th, 2021, 11:56am GMT
-
RN at South County Nursing & Rehab, Sharon Keller, of Narragansett, Passes at 61 - GoLocalProv
Posted: September 6th, 2021, 11:37pm GMT
-
Prolonged Survival Shown With SIRT and Y90 Plus Chemotherapy in Intrahepatic Cholangiocarcinoma - Targeted Oncology
Posted: September 5th, 2021, 6:00pm GMT
-
FDA grants orphan drug designation to gavo-cel for cholangiocarcinoma - Healio
Posted: September 5th, 2021, 10:21am GMT
-
Chirk woman's walking fundraiser after dad's devastating cancer diagnoses - Border Counties Advertizer
Posted: September 5th, 2021, 9:58am GMT
Chirk woman's walking fundraiser after dad's devastating cancer diagnoses Border Counties Advertizer -
SIRT With Y90 Plus Chemotherapy Extends Survival for Intrahepatic Cholangiocarcinoma - OncLive
Posted: September 4th, 2021, 2:08pm GMT
-
Chirk woman's fundraiser after dad's devastating cancer diagnoses - Denbighshire Free Press
Posted: September 4th, 2021, 4:00am GMT
Chirk woman's fundraiser after dad's devastating cancer diagnoses Denbighshire Free Press -
Chirk woman's fundraiser after dad's devastating cancer diagnoses - LeaderLive
Posted: September 4th, 2021, 4:00am GMT
-
'Landmark' FDA Approval of Tibsovo May Improve Outcomes for Liver Cancer Subtype - Curetoday.com
Posted: September 3rd, 2021, 6:26pm GMT
-
Devimistat Plus Gemcitabine/Cisplatin Moves to Phase 2 Setting in Frontline Biliary Tract Cancer - OncLive
Posted: September 3rd, 2021, 2:39pm GMT
-
Tibsovo receives FDA approval for advanced or metastatic cholangiocarcinoma - The Cancer Letter
Posted: September 3rd, 2021, 2:27pm GMT
-
TCR2 Therapeutics : TCR-2 THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR GAVO-CEL FOR THE TREATMENT OF CHOLANGIOCARCINOMA - marketscreener.com
Posted: September 3rd, 2021, 12:29pm GMT
-
In Brief This Week: Lantern Pharma, TCR2 Therapeutics, Huyabio - Precision Oncology News
Posted: September 3rd, 2021, 12:17pm GMT
In Brief This Week: Lantern Pharma, TCR2 Therapeutics, Huyabio Precision Oncology News -
Thermo Fisher (TMO) Gains Government Contract for Pipette Tip - Nasdaq
Posted: September 3rd, 2021, 11:09am GMT
-
'Whatever It Takes': Middlesboro mom shows superheroine strength in cancer battle - ABC 36 News - WTVQ
Posted: September 3rd, 2021, 10:32am GMT
-
'Whatever It Takes' — Middlesboro Mom Shows Superheroine Strength in Cancer Battle - UKNow
Posted: September 3rd, 2021, 7:52am GMT
-
RedHill Biopharma's opaganib shows inhibition of COVID-19 - SelectScience
Posted: September 3rd, 2021, 7:29am GMT
-
FDA Warns of Serious Risks, Including Death, With Tofacitinib - Pharmacy Practice News
Posted: September 2nd, 2021, 5:08pm GMT
FDA Warns of Serious Risks, Including Death, With Tofacitinib Pharmacy Practice News -
FDA Grants Orphan Drug Status to Gavocabtagene Autoleucel for Cholangiocarcinoma - OncLive
Posted: September 2nd, 2021, 3:23pm GMT
- FDA Grants Orphan Drug Status to Gavocabtagene Autoleucel for Cholangiocarcinoma OncLive
- TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma biospace.com
- TCR2 Therapeutics (TCRR) Gavo-cel Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma StreetInsider.com
- $TCRR TCR2 Therapeutics Gets FDA Orphan Drug Designation For Cholangiocarcinoma Treatment CML News
- TCR Therapeutics Gets FDA Orphan Designation for Gavo-cel in Bile-Duct Cancer >TCRR MarketWatch
- View Full Coverage on Google News
-
FDA Grants Orphan Drug Status to Gavocabtagene Autoleucel for Cholangiocarcinoma - OncLive
Posted: September 2nd, 2021, 3:23pm GMT
-
RedHill to Present at HCW & Cantor Conferences - StreetInsider.com
Posted: September 2nd, 2021, 12:38pm GMT
RedHill to Present at HCW & Cantor Conferences StreetInsider.com -
TCR Therapeutics gets FDA Orphan Drug status for gavo-cel cholangiocarcinoma treatment - Seeking Alpha
Posted: September 2nd, 2021, 11:42am GMT
-
New therapeutic method combined with synthetic CDK4/6 inhibitors for refractory cancers - Mirage News
Posted: September 2nd, 2021, 11:40am GMT
-
TCR2 Therapeutics Reports Received FDA Orphan Drug Designation For Gavo-cel For Treatment Of Cholangiocarcinoma - Benzinga
Posted: September 2nd, 2021, 11:20am GMT
-
Cholangiocarcinoma Foundation CEO named as a finalist in Cancer Community (C2) Awards - Curetoday.com
Posted: September 2nd, 2021, 11:14am GMT
-
FDA Approves Tibsovo Targeted Therapy for Cholangiocarcinoma - Cancer Health Treatment News
Posted: September 2nd, 2021, 10:10am GMT
FDA Approves Tibsovo Targeted Therapy for Cholangiocarcinoma Cancer Health Treatment News -
FDA Approvals Roundup: Skytrofa, Invega Hafyera, Briviact - Regulatory Focus
Posted: September 1st, 2021, 7:10pm GMT
FDA Approvals Roundup: Skytrofa, Invega Hafyera, Briviact Regulatory Focus -
Thermo Fisher Scientific, AstraZeneca Team up to Develop CDx for Targeted Drugs - Precision Oncology News
Posted: September 1st, 2021, 12:44pm GMT
Thermo Fisher Scientific, AstraZeneca Team up to Develop CDx for Targeted Drugs Precision Oncology News -
Thermo Fisher Scientific, AstraZeneca Team up to Develop CDx for Targeted Drugs - GenomeWeb
Posted: September 1st, 2021, 12:43pm GMT
-
A Look Back at the FDA News from August 2021 - Targeted Oncology
Posted: September 1st, 2021, 12:00pm GMT
A Look Back at the FDA News from August 2021 Targeted Oncology -
US FDA approval tracker: August - Vantage
Posted: September 1st, 2021, 10:00am GMT
US FDA approval tracker: August Vantage -
Innovent and GenFleet reach deal for KRAS inhibitor; TCR2 receives FDA's ODD on gavo-cel - Endpoints News
Posted: September 1st, 2021, 5:00am GMT
-
Melody Gale O'Connor | Obituaries | nny360.com - NNY360
Posted: August 31st, 2021, 5:08pm GMT
-
RayzeBio Expands Leadership Team With Susan Moran, M.D., as Chief Medical Officer; Kimberly Ma, M.S., as SVP of Clinical Operations; and Nicholas Smith, Ph.D., as SVP of Chemistry Innovation - Business Wire
Posted: August 31st, 2021, 10:00am GMT
-
RayzeBio Expands Leadership Team With Susan Moran, M.D., as Chief Medical Officer; Kimberly Ma, M.S., as SVP of Clinical Operations; and Nicholas Smith, Ph.D., as SVP of Chemistry Innovation - Yahoo Finance
Posted: August 31st, 2021, 10:00am GMT
-
Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed - PRNewswire
Posted: August 31st, 2021, 9:00am GMT
-
Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro - DocWire News
Posted: August 31st, 2021, 4:00am GMT
-
Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro - DocWire News
Posted: August 31st, 2021, 4:00am GMT
-
Study identifies actionable genes and candidate drugs in biliary tract cancer using a knowledgebase - News-Medical.net
Posted: August 31st, 2021, 3:06am GMT
-
Tcr2 (TCRR) gains 0.55% on Moderate Volume August 30 - Equities.com
Posted: August 31st, 2021, 11:38pm GMT
Tcr2 (TCRR) gains 0.55% on Moderate Volume August 30 Equities.com -
FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated UC - Clinical Oncology News
Posted: August 30th, 2021, 1:37pm GMT
FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated UC Clinical Oncology News -
FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated Cholangiocarcinoma - Clinical Oncology News
Posted: August 30th, 2021, 1:33pm GMT
FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated Cholangiocarcinoma Clinical Oncology News -
InnoCare Releases 2021 Half Year Results and Business Highlights - BioSpace
Posted: August 30th, 2021, 5:27am GMT
-
FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated UC - Pharmacy Practice News
Posted: August 30th, 2021, 5:00am GMT
FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated UC Pharmacy Practice News -
Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical - GuruFocus.com
Posted: August 30th, 2021, 11:00pm GMT
-
Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021 - Yahoo Finance
Posted: August 30th, 2021, 10:03pm GMT
-
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week - Benzinga
Posted: August 29th, 2021, 11:50am GMT
-
McClellan: Some good news, and many thank-yous - STLtoday.com
Posted: August 28th, 2021, 4:25pm GMT
McClellan: Some good news, and many thank-yous STLtoday.com -
FDA Updates: Genentech Withdraws Tecentriq Indication; New Approvals for Xarelto, Tibsovo - Managed Healthcare Executive
Posted: August 28th, 2021, 10:12am GMT
FDA Updates: Genentech Withdraws Tecentriq Indication; New Approvals for Xarelto, Tibsovo Managed Healthcare Executive -
Tcr2 (TCRR) gains 5.51% on Strong Volume August 27 - Equities.com
Posted: August 28th, 2021, 11:40pm GMT
Tcr2 (TCRR) gains 5.51% on Strong Volume August 27 Equities.com -
HI scientists publish research advancing understanding of bile duct cancer - Austin Daily Herald - Austin Herald
Posted: August 27th, 2021, 9:21pm GMT
-
HI scientists publish research advancing understanding of bile duct cancer - Austin Daily Herald - Austin Herald
Posted: August 27th, 2021, 9:20pm GMT
-
TIL Adoptive Cell Therapy Shows Clinical Promise in mNSCLC - Targeted Oncology
Posted: August 27th, 2021, 8:11pm GMT
TIL Adoptive Cell Therapy Shows Clinical Promise in mNSCLC Targeted Oncology -
$5.47 Million In Awards To Support Cancer Research At Texas A&M Health - Texas A&M University Today
Posted: August 27th, 2021, 2:57pm GMT
$5.47 Million In Awards To Support Cancer Research At Texas A&M Health Texas A&M University Today -
EC approves BioMarin drug as first treatment for children with common form of dwarfism; Servier sNDA wins approval - Endpoints News
Posted: August 27th, 2021, 1:00pm GMT
-
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for TIBSOVO - Entrepreneur
Posted: August 27th, 2021, 11:18am GMT
-
Tibsovo Approved for IDH1-Mutated Cholangiocarcinoma - Cancer Therapy Advisor
Posted: August 27th, 2021, 10:30am GMT
Tibsovo Approved for IDH1-Mutated Cholangiocarcinoma Cancer Therapy Advisor -
CStone Pharmaceuticals : Partner Servier Announces FDA Approval of TIBSOVO (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma - marketscreener.com
Posted: August 27th, 2021, 10:09am GMT
-
Geographic Disparities in Referral Rates and Oncologic Outcomes of Intrahepatic Cholangiocarcinoma: A Population-Based Study - DocWire News
Posted: August 27th, 2021, 4:00am GMT
-
Geographic Disparities in Referral Rates and Oncologic Outcomes of Intrahepatic Cholangiocarcinoma: A Population-Based Study - DocWire News
Posted: August 27th, 2021, 4:00am GMT
-
Geographic Disparities in Referral Rates and Oncologic Outcomes of Intrahepatic Cholangiocarcinoma: A Population-Based Study - DocWire News
Posted: August 27th, 2021, 4:00am GMT
-
Geographic Disparities in Referral Rates and Oncologic Outcomes of Intrahepatic Cholangiocarcinoma: A Population-Based Study - DocWire News
Posted: August 27th, 2021, 4:00am GMT
-
Geographic Disparities in Referral Rates and Oncologic Outcomes of Intrahepatic Cholangiocarcinoma: A Population-Based Study - DocWire News
Posted: August 27th, 2021, 4:00am GMT
-
Geographic Disparities in Referral Rates and Oncologic Outcomes of Intrahepatic Cholangiocarcinoma: A Population-Based Study - DocWire News
Posted: August 27th, 2021, 4:00am GMT
-
Tcr2 (TCRR) falls 3.62% for August 26 - Equities.com
Posted: August 27th, 2021, 11:41pm GMT
Tcr2 (TCRR) falls 3.62% for August 26 Equities.com -
Redhill (RDHL) gains 1.53% on Strong Volume August 26 - Equities.com
Posted: August 27th, 2021, 11:18pm GMT
-
5 for Good: Marblehead mother raises money to fight rare cancers - WCVB Boston
Posted: August 26th, 2021, 7:35pm GMT
-
Pharma built on Shire's old cancer business gets new FDA approval - Boston Business Journal - Boston Business Journal
Posted: August 26th, 2021, 2:28pm GMT
Pharma built on Shire's old cancer business gets new FDA approval - Boston Business Journal Boston Business Journal